About Circadian Therapeutics

Founded in 2016 as a spin-out from Oxford University, our world-leading science is based on the understanding of the molecular control of circadian rhythms, enabling us to develop unique therapeutics to treat serious diseases associated with disruption of the body clock.
Our experienced leadership team has a track record of building operational capabilities and shareholder value that delivers benefits and value for all stakeholders; patients, health professionals and investors.
Dr. Mike Snape
Chairman

Dr. Snape is a neurobiologist who has spent 32 years in the pharmaceutical industry working for large and emerging biopharmaceutical companies. He has experience founding and funding companies at inception through IPO on the public markets. His principal experience lies in the area of demonstrating clinical proof-of-concept with novel targeted therapeutics in rare diseases. He is named an inventor in numerous patents and is a scientific advisor to several patient foundations. He earned a PhD in neurobiology from London University after study at Maudsley and Bethlem Hospital and holds a faculty position at Case Western University.

Dr. Mark Sampson
Chief Executive Officer

Most recently Chief Medical Officer of Shield Therapeutics, Dr Sampson has had a distinguished, 30-year career as a pharmaceutical physician in both Clinical Development and Medical Affairs roles across pharmaceutical, biotech and consumer products companies including Gilead, Amgen and SmithKline Beecham. 

Julia Jones FCA
Chief Finance Officer

After graduating from Loughborough University in 1997, Julia joined PricewaterhouseCoopers and qualified as a Chartered Accountant in 2001. Julia then gained a broad range of experience with key finance positions in Industry. For the last thirteen years, as the founder and Managing Director of Archangel Accounting Ltd, Julia has provided tailor-made support to many companies, including those with venture capital backing, privately owned businesses, and charities.

Glen Leighton
Non-Exec Director

Glenn is the founder of Hydrophis Gas which is developing new chemistry to capture marine CO2 and convert it into bicarbonate powder through biomimicry. He is Chairman of Hutano Diagnostics, making aptamer-based rapid tests for viral illnesses such as Covid-19. Formerly an investment banker, he has over 23 years’ experience of growing businesses through raising debt and equity, corporate (re)structuring and regulatory advisory. He has a PhD from Oxford where he was a Rhodes Scholar in the 1990s, and undergraduate law degrees from universities in Japan and Australia.

Prof Russell Foster, CBE, FRS
Director & Academic Founder
Russell Foster is the Head of the Nuffield Laboratory of Ophthalmology, Director of the Sleep and Circadian Research Institute and a Fellow of Brasenose College Oxford.
Prof Aarti Jagannath
Academic Founder
Assoc. Prof. Aarti Jagannath read for a Master’s and DPhil at the University of Oxford in biomedical sciences and subsequently started research on circadian rhythms as post-doctoral fellow.
Read more.

Aarti’s pioneering findings on the molecular underpinnings of circadian rhythms have been published in prestigious peer reviewed journals including Cell and Current Biology.

Aarti currently runs her own research group at the University of Oxford as a BBSRC David Phillips Fellow and works on the molecular mechanisms by which circadian rhythms are entrained, or are set to the right time. She was awarded the L’Oreal Women in Science Fellowship in 2015.

Dr Sridhar Vasudevan
Academic Founder
Sridhar Vasudevan read for an MSc and DPhil at the University of Oxford in the Department of Pharmacology. As a BBSRC-Royal Society of Edinburgh Enterprise Fellow, he worked on several successful drug discovery projects, including the translation of first in class molecules from the laboratory to early phase clinical development candidates in the area of neuroscience.
Read more.

His pioneering work has been published in several prestigious peer-review journals including; Nature Chemical Biology and Nature Communications, he remains widely cited.

Sri currently heads his own laboratory at Oxford working on the identification and targeting of novel molecular pathways leading to the potential modulation of circadian rhythms and sleep.

Virtual Team
Boyds Ltd

Development and Regulatory Support & Consultancy
Website

Consultants
Medical input as required through a network of experienced consultants
Labrador Technology Ltd

Project Management & IT
Website

Corporate Advisors
James Cowper Kreston

Accounts
Website

Stratagem Ltd

Intellectual Property
Website

Penningtons Manches Ltd

Legal
Website

Therapeutics that treat the causes, not just the symptoms

Contact

Oxford Centre for Innovation
New Road
Oxford
OX1 1BY

contact@circadiantherapeutics.com

+44 (0) 1865 546581

Registered Office

Oxford Centre for Innovation
New Road
Oxford
OX1 1BY

Registered No 10283353.

PRIVACY POLICY

© Circadian Therapeutics 2018.
All rights reserved.

Website Design by Brand Cooke

Accessibility